Your Guide to Partnering with Us
Your Guide to Partnering with Us
Search
1885-1948: Innovative Beginnings | Boehringer Ingelheim US
Click here to read an in-depth history of Boehringer Ingelheim's formation, early days and what led us to being the global pharmaceutical company of today.
Roger’s sarcoma experience
Our aspiration is to deliver more treatment options for people with cancer today, tomorrow and beyond. Roger, who lives with sarcoma, sheds light on why this is so important.
Occupational Health and Safety
Occupational Health and Safety
Investigating MDM2-p53 in cancer
Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.
Corporate Compliance Program
Corporate Compliance Program
Immunology
Immunology
Innovation in CardioMetabolic Disease Research
Innovation in CardioMetabolic Disease Research
Retinal Health
Retinal Health
Mental Health disorders
Mental Health disorders
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Empowering Employees to be Their Own Superheroes
Empowering Employees to be Their Own Superheroes
BI initiates Study of Sequencing in EGFR Lung Cancer | BI US
Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.
Legal & Compliance
Legal & Compliance
Germany
Germany
About Boehringer Ingelheim Academy
About Boehringer Ingelheim Academy
Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Innovation in Oncology and Cancer Immunology
Cancer research is one of the cornerstones of BI's research and has resulted in the launch of 2 products for the treatment of non-small cell lung cancer.
CIA Reporting Requirements
CIA Reporting Requirements
Technologies
Technologies
Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
Veterinary Public Health
Veterinary Public Health
We’re All In
We’re All In
Partnering Culture
BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.